Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Allevia 120mg (fexofenadine) not yet in UK despite POM to GSL switch

Allevia 120mg (fexofenadine) tablets “are not currently marketed in the UK”, despite the hayfever product switching from POM to GSL at the end of last year, Sanofi has told C+D.

On December 22, 2020, the Medicines Healthcare and Regulatory Authority (MHRA) published a public assessment report reclassifying hayfever tablets Allevia 120mg (fexofenadine) from a prescription only medicine (POM) to general sales list (GSL).

The switch was met with fanfare from pharmacy professionals on social media, as pharmacy teams continue to receive more and more requests from patients for hayfever remedies.

However, Sanofi – parent company of Aventis Pharma who applied for the reclassification – told C+D that despite the successful reclassification at the end of last year, Allevia 120mg tablets “are not currently marketed in the United Kingdom”.

“Sanofi does not have an estimated date of launch that we are able to provide, nor any further information regarding the…next steps for this product,” the manufacturer added.

“Sanofi's POM fexofenadine hydrochloride tablets are currently in stock,” it stressed.

The MHRA told C+D that while it “grants an authorisation to market a product, this does not mean that the marketing authorisation holder will necessarily choose to market the medicine immediately after grant”.

Read C+D's guide on what pharmacists need to know, following the POM to GSL switch.

Have you had an increase in requests from patients suffering with hayfever?

Related Content

Topics



Pharmacy Dispenser/ Technician
Bethnal Green North, London
Salary: Up to £30,000

Apply Now
UsernamePublicRestriction

Register

CD007256

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel